Cellosaurus logo
expasy logo

Cellosaurus HEY (CVCL_0297)

[Text version]
Cell line name HEY
Synonyms Hey
Accession CVCL_0297
Resource Identification Initiative To cite this cell line use: HEY (RRID:CVCL_0297)
Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Part of: MD Anderson Cell Lines Project.
Population: Caucasian.
Doubling time: 30 hours (PubMed=4016745); 20.53 hours (GrayJW panel).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Array-based CGH.
Omics: CRISPR phenotypic screen.
Omics: Deep exome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: Genome sequenced.
Omics: Protein expression by reverse-phase protein arrays.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
Derived from site: In situ; Ovary; UBERON=UBERON_0000992.
Sequence variations
  • Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Glu (c.1391G>A); ClinVar=VCV000013964; Zygosity=Homozygous (Cosmic-CLP; DepMap).
  • Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (Cosmic-CLP; DepMap).
HLA typing Source: PubMed=26589293
Class I
HLA-AA*02:01,29:02
HLA-BB*44:02,45:01
HLA-CC*05:01,06:02
Genome ancestry Source: PubMed=30894373

Origin% genome
African0.88
Native American0.22
East Asian, North0.66
East Asian, South0.27
South Asian0
European, North67.37
European, South30.59
Disease High grade ovarian serous adenocarcinoma (NCIt: C105555)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_4995 (HX/62)
Children:
CVCL_L041 (HEY A4)CVCL_8878 (HEY A8)CVCL_L040 (HEY AS1)
CVCL_X009 (HEY C2)CVCL_AZ64 (HEY-1B)CVCL_2Z96 (HEY-T30)
CVCL_JZ11 (HEY/GFP)
Sex of cell Female
Age at sampling Age unspecified
Category Cancer cell line
STR profile Source(s): Cosmic-CLP; PubMed=22710073; PubMed=25877200; PubMed=30485824

Markers:
AmelogeninX
CSF1PO10,11
D2S133824,25
D3S135816
D5S81811,12 (Cosmic-CLP; PubMed=22710073; PubMed=25877200)
11,12,13 (PubMed=30485824)
D7S82012
D8S117913
D13S31711
D16S5398,12
D18S5115
D19S43313,14
D21S1130
FGA20,21
Penta D9,13
Penta E7,13
TH018,9.3
TPOX11
vWA16,17

Run an STR similarity search on this cell line
Web pages https://www.cedarlanelabs.com/Products/Detail/CLU302?lob=Cellutions
https://tcpaportal.org/mclp/
Publications

PubMed=4016745
Buick R.N., Pullano R., Trent J.M.
Comparative properties of five human ovarian adenocarcinoma cell lines.
Cancer Res. 45:3668-3676(1985)

PubMed=3731068
Baumal R., Law J., Buick R.N., Kahn H., Yeger H., Sheldon K., Colgan T., Marks A.
Monoclonal antibodies to an epithelial ovarian adenocarcinoma: distinctive reactivity with xenografts of the original tumor and a cultured cell line.
Cancer Res. 46:3994-4000(1986)

PubMed=12960427; DOI=10.1091/mbc.E03-05-0279
Schaner M.E., Ross D.T., Ciaravino G., Sorlie T., Troyanskaya O.G., Diehn M., Wang Y.C., Duran G.E., Sikic T.L., Caldeira S., Skomedal H., Tu I.-P., Hernandez-Boussard T., Johnson S.W., O'Dwyer P.J., Fero M.J., Kristensen G.B., Borresen-Dale A.-L., Hastie T., Tibshirani R., van de Rijn M., Teng N.N.H., Longacre T.A., Botstein D., Brown P.O., Sikic B.I.
Gene expression patterns in ovarian carcinomas.
Mol. Biol. Cell 14:4376-4386(2003)

PubMed=19926575; DOI=10.1309/AJCPTK87EMMIKPFS
DeRycke M.S., Andersen J.D., Harrington K.M., Pambuccian S.E., Kalloger S.E., Boylan K.L.M., Argenta P.A., Skubitz A.P.N.
S100A1 expression in ovarian and endometrial endometrioid carcinomas is a prognostic indicator of relapse-free survival.
Am. J. Clin. Pathol. 132:846-856(2009)

PubMed=20204287; DOI=10.3892/or_00000728
Langland G.T., Yannone S.M., Langland R.A., Nakao A., Guan Y.-H., Long S.B.T., Vonguyen L., Chen D.J., Gray J.W., Chen F.-Q.
Radiosensitivity profiles from a panel of ovarian cancer cell lines exhibiting genetic alterations in p53 and disparate DNA-dependent protein kinase activities.
Oncol. Rep. 23:1021-1026(2010)

PubMed=22710073; DOI=10.1016/j.ygyno.2012.06.017
Korch C.T., Spillman M.A., Jackson T.A., Jacobsen B.M., Murphy S.K., Lessey B.A., Jordan V.C., Bradford A.P.
DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination.
Gynecol. Oncol. 127:241-248(2012)

PubMed=23415752; DOI=10.1016/j.molonc.2012.12.007
Stordal B., Timms K., Farrelly A., Gallagher D., Busschots S., Renaud M., Thery J., Williams D., Potter J., Tran T., Korpanty G., Cremona M., Carey M.S., Li J., Li Y., Aslan O., O'Leary J.J., Mills G.B., Hennessy B.T.
BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation.
Mol. Oncol. 7:567-579(2013)

PubMed=24023729; DOI=10.1371/journal.pone.0072162
Anglesio M.S., Wiegand K.C., Melnyk N., Chow C., Salamanca C.M., Prentice L.M., Senz J., Yang W., Spillman M.A., Cochrane D.R., Shumansky K., Shah S.P., Kalloger S.E., Huntsman D.G.
Type-specific cell line models for type-specific ovarian cancer research.
PLoS ONE 8:E72162-E72162(2013)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=25877200; DOI=10.1038/nature14397
Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.
A resource for cell line authentication, annotation and quality control.
Nature 520:307-311(2015)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5
Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Genome Med. 7:118.1-118.7(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

PubMed=30485824; DOI=10.1016/j.celrep.2018.10.096
Papp E., Hallberg D., Konecny G.E., Bruhm D.C., Adleff V., Noe M., Kagiampakis I., Palsgrove D., Conklin D., Kinose Y., White J.R., Press M.F., Drapkin R.I., Easwaran H., Baylin S.B., Slamon D.J., Velculescu V.E., Scharpf R.B.
Integrated genomic, epigenomic, and expression analyses of ovarian cancer cell lines.
Cell Rep. 25:2617-2633(2018)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=30971826; DOI=10.1038/s41586-019-1103-9
Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M., Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R., Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P., van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L., Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Nature 568:511-516(2019)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

Cross-references
Cell line collections (Providers) CLS; 305017
Cell line databases/resources MCCL; MCC:0000188
cancercelllines; CVCL_0297
Cell_Model_Passport; SIDM00968
Cosmic-CLP; 1479988
DepMap; ACH-002140
Anatomy/cell type resources BTO; BTO:0002590
Biological sample resources BioSample; SAMN03473280
CRISP screens repositories BioGRID_ORCS_Cell_line; 866
Chemistry resources ChEMBL-Cells; CHEMBL3308082
ChEMBL-Targets; CHEMBL613869
GDSC; 1479988
PharmacoDB; HEY_541_2019
PubChem_Cell_line; CVCL_0297
Encyclopedic resources Wikidata; Q54883211
Experimental variables resources EFO; EFO_0006580
Gene expression databases ArrayExpress; E-MTAB-2706
ArrayExpress; E-MTAB-3610
GEO; GSM659377
GEO; GSM1340581
GEO; GSM1669880
Polymorphism and mutation databases Cosmic; 1102812
Cosmic; 1524358
IARC_TP53; 28489
Proteomic databases PRIDE; PXD030304
Sequence databases EGA; EGAS00001000610
EGA; EGAS00001000978
Entry history
Entry creation04-Apr-2012
Last entry update30-Jan-2024
Version number37